Abstract Context The European Association of Urology Guideline Panel for Renal Cell
Carcinoma (RCC) has prepared evidence-based guidelines and recommendations for RCC …

Over the past decade, the treatment landscape for patients with metastatic renal cell
carcinoma (RCC) has evolved dramatically. The therapeutic options available have …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

Background Despite advances in the first-line treatment of metastatic renal cell carcinoma
(RCC), there is an unmet need for options to address disease progression during or after …

Purpose Older adults are at increased risk for chemotherapy toxicity, and standard oncology
assessment measures cannot identify those at risk. A predictive model for chemotherapy …

Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell
renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible …

Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune
checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed …